Clinical trial
A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy
NCT05973864 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study to Evaluate CAPecitabine Plus Pembrolizumab as Post-operative Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Chemo-immunotherapy
- Lead sponsor
- UNICANCER
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- March 11, 2025
- Completion date
- August 31, 2028
- Enrollment
- 220 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.